Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MD Stock Forecast 2025-2026
$14.88
Current Price
$1.22B
Market Cap
Buy 3
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to MD Price Targets
+41.1%
To High Target of $21.00
+7.5%
To Median Target of $16.00
-5.9%
To Low Target of $14.00
MD Price Momentum
+2.4%
1 Week Change
+13.2%
1 Month Change
+91.0%
1 Year Change
+13.4%
Year-to-Date Change
-15.8%
From 52W High of $17.67
+124.8%
From 52W Low of $6.62
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching MEDNAX (MD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MD and similar high-potential opportunities.
Latest MD Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, MD has a neutral consensus with a median price target of $16.00 (ranging from $14.00 to $21.00). The overall analyst rating is Buy (7.5/10). Currently trading at $14.88, the median forecast implies a 7.5% upside. This outlook is supported by 3 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jack Slevin at Jefferies, suggesting a 5.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MD Analyst Ratings
3
Buy
5
Hold
0
Sell
MD Price Target Range
Low
$14.00
Average
$16.00
High
$21.00
Current: $14.88
Latest MD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | UBS | A.J. Rice | Neutral | Maintains | $16.00 |
| May 8, 2025 | Macquarie | Tao Qiu | Outperform | Maintains | $20.00 |
| Apr 11, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $16.00 |
| Feb 21, 2025 | UBS | A.J. Rice | Neutral | Maintains | $18.50 |
| Feb 21, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $18.00 |
| Jan 6, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $15.00 |
| Dec 16, 2024 | Macquarie | Tao Qiu | Outperform | Initiates | $18.00 |
| Nov 19, 2024 | Mizuho | Ann Hynes | Neutral | Maintains | $15.00 |
| Nov 5, 2024 | Jefferies | Jack Slevin | Buy | Maintains | $18.00 |
| Nov 5, 2024 | UBS | A.J. Rice | Neutral | Maintains | $16.50 |
| Nov 4, 2024 | Deutsche Bank | Pito Chickering | Hold | Maintains | $15.00 |
| Nov 4, 2024 | Mizuho | Ann Hynes | Neutral | Maintains | $15.00 |
| Nov 4, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $16.00 |
| Oct 7, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $13.00 |
| Sep 26, 2024 | Jefferies | Jack Slevin | Buy | Upgrade | $14.00 |
| Aug 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $10.00 |
| Aug 9, 2024 | UBS | A.J. Rice | Neutral | Maintains | $10.50 |
| Jul 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $8.00 |
| Jun 7, 2024 | Deutsche Bank | Pito Chickering | Hold | Upgrade | $8.00 |
| May 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $10.00 |
Pediatrix Medical Group, Inc. (MD) Competitors
The following stocks are similar to MEDNAX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pediatrix Medical Group, Inc. (MD) Financial Data
Pediatrix Medical Group, Inc. has a market capitalization of $1.22B with a P/E ratio of 8.0x. The company generates $1.98B in trailing twelve-month revenue with a -4.2% profit margin.
Revenue growth is -7.4% quarter-over-quarter, while maintaining an operating margin of +8.4% and return on equity of -10.0%.
Valuation Metrics
Market Cap
$1.22B
Enterprise Value
$1.63B
P/E Ratio
8.0x
PEG Ratio
9.3x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
-7.4%
Gross Margin
+22.4%
Operating Margin
+8.4%
Net Margin
-4.2%
EPS Growth
+413.9%
Financial Health
Cash/Price Ratio
+17.5%
Current Ratio
1.8x
Debt/Equity
83.0x
ROE
-10.0%
ROA
+5.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pediatrix Medical Group, Inc. (MD) Business Model
About Pediatrix Medical Group, Inc.
What They Do
Provides specialized healthcare services for women and children.
Business Model
The company operates by providing physician services focused on neonatal, maternal-fetal, and pediatric cardiology, generating revenue through clinical staffing, administrative support, and healthcare management solutions. It partners with hospitals and clinics to enhance patient care, ensuring a steady demand for its specialized services.
Additional Information
Pediatrix Medical Group plays a vital role in the healthcare industry by addressing the critical needs of vulnerable populations. Its comprehensive service offerings contribute to improved outcomes in neonatal and pediatric care, positioning the company favorably in a growing and dynamic healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
4,120
CEO
Mr. Mark S. Ordan
Country
United States
IPO Year
1995
Website
www.pediatrix.comPediatrix Medical Group, Inc. (MD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
May 14, 2025
By Zacks Equity Research
Tale of the Tape
Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs
MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.
May 09, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Pediatrix Medical Group (MD) has shown strong momentum and is considered a reasonable investment option, passing through the 'Fast-Paced Momentum at a Bargain' screening.
Why It Matters
Pediatrix Medical Group shows strong momentum and reasonable pricing, indicating potential for growth, making it an attractive stock option for value-focused investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
MD projects adjusted EBITDA for 2025 to range from $220 million to $240 million.
Why It Matters
MD's projected adjusted EBITDA signals potential revenue growth, impacting profitability forecasts and investor confidence in 2025, which can influence stock performance and valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Pediatrix Medical Group, Inc. will hold its Q1 2025 earnings conference call on May 6, 2025, at 9:00 AM ET, with key executives and analysts participating.
Why It Matters
The conference call indicates potential insights into Pediatrix's financial health and future strategy, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pediatrix Medical Group has announced its first quarter results, as reported in a Business Wire release. Further details on financial performance were not provided in the excerpt.
Why It Matters
Pediatrix Medical Group's quarterly results can impact its stock performance and investor sentiment, reflecting financial health and growth potential, influencing investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pediatrix Medical Group (MD) reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.25, and up from $0.20 per share year-over-year.
Why It Matters
Pediatrix Medical Group's earnings beat expectations and showed year-over-year growth, signaling strong financial performance that may boost investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in Medical Services stocks are evaluating Pediatrix Medical Group (MD) and HealthEquity (HQY) for potential value opportunities.
Why It Matters
The comparison between Pediatrix Medical Group and HealthEquity highlights potential investment opportunities and value propositions in the Medical Services sector, influencing stock selection.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About MD Stock
What is Pediatrix Medical Group, Inc.'s (MD) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Pediatrix Medical Group, Inc. (MD) has a median price target of $16.00. The highest price target is $21.00 and the lowest is $14.00.
Is MD stock a good investment in 2025?
According to current analyst ratings, MD has 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MD stock?
Wall Street analysts predict MD stock could reach $16.00 in the next 12 months. This represents a 7.5% increase from the current price of $14.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pediatrix Medical Group, Inc.'s business model?
The company operates by providing physician services focused on neonatal, maternal-fetal, and pediatric cardiology, generating revenue through clinical staffing, administrative support, and healthcare management solutions. It partners with hospitals and clinics to enhance patient care, ensuring a steady demand for its specialized services.
What is the highest forecasted price for MD Pediatrix Medical Group, Inc.?
Price targets from Wall Street analysts for MD are not currently available. The stock is trading at $14.88.
What is the lowest forecasted price for MD Pediatrix Medical Group, Inc.?
The lowest price target for MD is $14.00 from Jack Slevin at Jefferies, which represents a -5.9% decrease from the current price of $14.88.
What is the overall MD consensus from analysts for Pediatrix Medical Group, Inc.?
The overall analyst consensus for MD is neutral. Out of 18 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are MD stock price projections?
Stock price projections, including those for Pediatrix Medical Group, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 8:56 AM UTC